These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36270620)

  • 1. Pulmonary artery pressure-directed therapies in pulmonary arterial hypertension?
    D'Alto M; Naeije R
    Vascul Pharmacol; 2022 Dec; 147():107124. PubMed ID: 36270620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary pressure recovery in idiopathic, hereditary and drug and toxin-induced pulmonary arterial hypertension: determinants and clinical impact.
    Badagliacca R; Vizza CD; Lang I; Sadushi-Kolici R; Papa S; Manzi G; Filomena D; Ogawa A; Shimokawahara H; Matsubara H
    Vascul Pharmacol; 2022 Oct; 146():107099. PubMed ID: 36058492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenteral Prostanoids in Pediatric Pulmonary Arterial Hypertension: Start Early, Dose High, Combine.
    Douwes JM; Zijlstra WMH; Rosenzweig EB; Ploegstra MJ; Krishnan US; Haarman MG; Roofthooft MTR; Postmus D; Hillege HL; Ivy DD; Berger RMF
    Ann Am Thorac Soc; 2022 Feb; 19(2):227-237. PubMed ID: 34181866
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
    Ruopp NF; Cockrill BA
    JAMA; 2022 Apr; 327(14):1379-1391. PubMed ID: 35412560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension.
    Badagliacca R; D'Alto M; Ghio S; Argiento P; Bellomo V; Brunetti ND; Casu G; Confalonieri M; Corda M; Correale M; D'Agostino C; De Michele L; Galgano G; Greco A; Lombardi C; Manzi G; Mercurio V; Mulè M; Paciocco G; Papa S; Romeo E; Scelsi L; Stolfo D; Vitulo P; Naeije R; Vizza CD
    Am J Respir Crit Care Med; 2021 Feb; 203(4):484-492. PubMed ID: 32857597
    [No Abstract]   [Full Text] [Related]  

  • 6. Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?
    Vizza CD; Lang IM; Badagliacca R; Benza RL; Rosenkranz S; White RJ; Adir Y; Andreassen AK; Balasubramanian V; Bartolome S; Blanco I; Bourge RC; Carlsen J; Camacho REC; D'Alto M; Farber HW; Frantz RP; Ford HJ; Ghio S; Gomberg-Maitland M; Humbert M; Naeije R; Orfanos SE; Oudiz RJ; Perrone SV; Shlobin OA; Simon MA; Sitbon O; Torres F; Luc Vachiery J; Wang KY; Yacoub MH; Liu Y; Golden G; Matsubara H
    Am J Respir Crit Care Med; 2022 Apr; 205(7):751-760. PubMed ID: 34905704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive estimation of PA pressure, flow, and resistance with CMR imaging: derivation and prospective validation study from the ASPIRE registry.
    Swift AJ; Rajaram S; Hurdman J; Hill C; Davies C; Sproson TW; Morton AC; Capener D; Elliot C; Condliffe R; Wild JM; Kiely DG
    JACC Cardiovasc Imaging; 2013 Oct; 6(10):1036-1047. PubMed ID: 23769494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension.
    D'Alto M; Badagliacca R; Argiento P; Romeo E; Farro A; Papa S; Sarubbi B; Russo MG; Vizza CD; Golino P; Naeije R
    Chest; 2020 Feb; 157(2):376-383. PubMed ID: 31563498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk factors for death and the clinical features of different subtypes of patients with pulmonary arterial hypertension related to congenital heart disease].
    Xu ZY; Li QQ; Zhang C; Zhang HS; Gu H
    Zhonghua Xin Xue Guan Bing Za Zhi; 2020 Apr; 48(4):315-322. PubMed ID: 32370483
    [No Abstract]   [Full Text] [Related]  

  • 10. Pulmonary Arterial Hypertension: a Pharmacotherapeutic Update.
    Coons JC; Pogue K; Kolodziej AR; Hirsch GA; George MP
    Curr Cardiol Rep; 2019 Nov; 21(11):141. PubMed ID: 31758342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnancy in Patients with Pulmonary Arterial Hypertension in Light of New ESC Guidelines on Pulmonary Hypertension.
    Barańska-Pawełczak K; Wojciechowska C; Jacheć W
    Int J Environ Res Public Health; 2023 Mar; 20(5):. PubMed ID: 36901635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Golden Ratio and the Proportionality Between Pulmonary Pressure Components in Pulmonary Arterial Hypertension.
    Chemla D; Boulate D; Weatherald J; Lau EMT; Attal P; Savale L; Montani D; Fadel E; Mercier O; Sitbon O; Humbert M; Hervé P
    Chest; 2019 May; 155(5):991-998. PubMed ID: 30594558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Pulmonary Fibrosis and Emphysema With Pulmonary Hypertension: Cases Report.
    Robledo GC; Hernández MYJ; Lucas SAG; Delgado FRC
    Curr Probl Cardiol; 2022 Apr; 47(4):100856. PubMed ID: 33994029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.
    Vilela VS; Dias MM; Salgado ÂA; da Silva BRA; Lopes AJ; Bessa EJC; Bruno LP; da Costa CH; Levy RA; Rufino R
    BMC Pulm Med; 2021 Jul; 21(1):251. PubMed ID: 34325685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating Riociguat in the Treatment of Pulmonary Arterial Hypertension: A Real-World Perspective.
    Mihalek AD; Scott CD; Mazimba S
    Vasc Health Risk Manag; 2022; 18():823-832. PubMed ID: 36299800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Sildenafil reduces pressure and pulmonary resistance and increases susceptibility of pulmonary arteries to nitric oxide in primary pulmonary arterial hypertension].
    Wodniecki J; Jacheć W; Poloński L; Tomasik AR; Wojciechowska C; Foremny A
    Przegl Lek; 2005; 62(2):135-8. PubMed ID: 16095162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension.
    Mulvaney EP; Reid HM; Bialesova L; Bouchard A; Salvail D; Kinsella BT
    BMC Pulm Med; 2020 Apr; 20(1):85. PubMed ID: 32252727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy Improved Pulmonary Arterial Hypertension in a Patient with Chronic-Active Epstein-Barr Virus Infection.
    Akagi S; Miki T; Sando Y; Fujii N; Sarashina T; Nakamura K; Ito H
    Int Heart J; 2020 Jan; 61(1):191-194. PubMed ID: 31956153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Porto-pulmonary arterial hypertension: Translation of pathophysiological concepts to the bedside.
    Mazzola M; Madonna R; Badagliacca R; Caterina R
    Vascul Pharmacol; 2022 Aug; 145():107022. PubMed ID: 35738494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemodynamic effects of PAH-targeted therapies in pulmonary hypertension due to lung disease: A systematic review and meta-analysis.
    Farmakis IT; Vazakidis P; Doundoulakis I; Arvanitaki A; Zafeiropoulos S; Boutou A; Karvounis H; Giannakoulas G
    Pulm Pharmacol Ther; 2021 Jun; 68():102036. PubMed ID: 33979684
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.